Cite
Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL).
MLA
Topp, Max S., et al. “Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL).” Biology of Blood & Marrow Transplantation, vol. 26, Mar. 2020, p. S101. EBSCOhost, https://doi.org/10.1016/j.bbmt.2019.12.603.
APA
Topp, M. S., van Meerten, T., Houot, R., Minnema, M., Milpied, N., Lugtenburg, P. J., Thieblemont, C., Wermke, M., Song, K., Avivi, I., Kuruvilla, J., Dührsen, U., Chu, R., Zheng, L., Plaks, V., Kerber, A., & Kersten, M. J. (2020). Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). Biology of Blood & Marrow Transplantation, 26, S101. https://doi.org/10.1016/j.bbmt.2019.12.603
Chicago
Topp, Max S., Tom van Meerten, Roch Houot, Monique Minnema, Noel Milpied, Pieternella J. Lugtenburg, Catherine Thieblemont, et al. 2020. “Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL).” Biology of Blood & Marrow Transplantation 26 (March): S101. doi:10.1016/j.bbmt.2019.12.603.